Pancreatic cancer
Conditions
Interventions
Peripheral blood collection and an additional biopsy in a subset of included patients.
Sponsors
Erasmus MC
Eligibility
Inclusion criteria
Inclusion criteria: • Cytological or histologically confirmed PDAC, irrespective of treatment status; • Age > 18 years and = 60 years at date of primary diagnosis; • Performance status of ECOG 0-2; • Estimated life expectancy of at least 12 weeks; • Written informed consent.
Exclusion criteria
Exclusion criteria: • Unwilling to know if there are any alterations which might be associated with genetic predisposition of cancer; • Patient with locally-advanced PDAC or local-recurrence of PDAC with no histological tissue available for NGS.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of the study is defined as the frequency of clinically actionable alterations in PDAC patients = 60 years old. | — |
Secondary
| Measure | Time frame |
|---|---|
| • To assess the feasibility of nationwide NGS in a clinically relevant manner in the Netherlands. • To determine the impact of NGS on clinical management in PDAC patients = 60 years. • To identify subgroups of PDAC patients with a high incidence of actionable genetic alterations. • To identify genomic predictors of therapy response and long term oncological outcomes. • To determine the potential of ctDNA for the identification of genetic alterations in pancreatic cancer patients. | — |
Contacts
Public ContactGaby Strijk
Erasmus MC
Outcome results
None listed